

Uzbekistan: COVID-19 Emergency Response

| Project Name | COVID-19 Emergency Response | | |
|---|--|--|--|
| Project Number | 54390-001 | | |
| Country | Uzbekistan | | |
| Project Status | Approved | | |
| Project Type / Modality of Assistance | Grant | | |
| Source of Funding / Amount | Grant 0738-UZB: COVID-19 Emergency Response | | |
| | APDRF Government of Japan for COVID19 US\$ 3.00 million | | |
| Strategic Agendas | Inclusive economic growth | | |
| Drivers of Change | Governance and capacity development | | |
| Sector / Subsector | Health - Disease control of communicable disease | | |
| Gender Equity and Mainstreaming | No gender elements | | |
| Description | The Ministry of Investments and Foreign Trade (MIFT) of Uzbekistan requested ADB to provide emergency grant assistance to support the Government's ongoing response, particularly its need to procure medicines and other medical supplies for the treatment of COVID-19-infected patients. The Asia Pacific Disaster Response Fund (APDRF) grant will support procurement of medicines and other medical consumables, including personal protective equipment and medical supplies for the treatment of COVID-19-infected patients. | | |
| Project Rationale and Linkage to Country/Regional Strategy | On 26 April 2020, the Government requested emergency assistance from ADB to upgrade and expand the national laboratory and surveillance system and to provide budget support. In response, ADB developed a comprehensive assistance package to increase Uzbekistan's resilience to the COVID-19 pandemic and future public health emergencies. On 30 April 2020, ADB provided grant resources of about \$1.6 million under regional technical assistance for the procurement of medical supplies such as oxygen respirators and personal protective equipment. ADB also mobilized \$19.5 million from the Primary Health Care Improvement Project to purchase ventilators to support treatment of COVID-19 patients. On 25 June 2020, ADB approved a \$500 million loan from ADB's ordinary capital resources for the COVID-19 Active Response and Expenditure Support (CARES) Program. The program aims to support the Government's immediate efforts to mitigate the adverse impacts of COVID-19 on the population's health, incomes and economic opportunities, and to support macroeconomic stability. On 30 July 2020, ADB approved a \$100 million to finance the \$200 million COVID-19 Emergency Response Project, which was cofinanced by the Asian Infrastructure Investment Bank (AIIB) with a \$100 million loan approved on 13 August 2020. The project will support the testing, surveillance, and case management of COVID-19 in Uzbekistan through three outputs: (i) national laboratory system strengthened, (ii) national surveillance and response system established for COVID-19, and (iii) COVID-19 treatment capacity expanded. Activities will be coordinated with and complement assistance from the World Bank and other partners, and help fill gaps in medical equipment and supplies. Other support included technical assistance, training, equipment, and supplies. In its letter of 13 August 2020, the Ministry of Investments and Foreign Trade (MIFT) requested ADB to provide emergency grant assistance to support the Government's ongoing response, particularly its need to procure medici | | |
| Impact | To alleviate the financial resources constraint to meet immediate needs and deliver appropriate medicines and other medical consumables, including personal protective equipment and medical supplies | | |
| Project Outcome | | | |
| Description of Outcome | Improved Government of Uzbekistan (GOU) preparedness to respond to the surge in COVID-19 cases registered over the past two months. | | |
| Progress Toward Outcome | | | |
| Implementation Progress | | | |
| Description of Project Outputs | Financial support provided to the government to meet immediate needs and deliver appropriate medical services to combat COVID-19 outbreak. | | |
| Status of Implementation Progr | ess (Outputs, Activities, and Issues) | | |
| Geographical Location | Nation-wide | | |
| Safeguard Categories | | | |
| Environment | FI | | |
| Involuntary Resettlement | FI | | |
| Indigenous Peoples | FI | | |
| Summary of Environmental and | l Social Aspects | | |

| Environmental Aspects | | | | | |
|--|---|--|--|--|--|
| Involuntary Resettlement | | | | | |
| Indigenous Peoples | | | | | |
| Stakeholder Communication, Participation, and Consultation | | | | | |
| During Project Design | | | | | |
| During Project Implementation | | | | | |
| | | | | | |
| Responsible ADB Officer | Mamatkulov, Raushanbek | | | | |
| Responsible ADB Department | Central and West Asia Department | | | | |
| Responsible ADB Division | Uzbekistan Resident Mission | | | | |
| Executing Agencies | Ministry of Health 12 Navoi Street Tashkent, Uzbekistan | | | | |
| Timetable | | | | | |
| Concept Clearance | | | | | |
| Fact Finding | | | | | |
| MRM | | | | | |
| Approval | 14 Sep 2020 | | | | |
| Last Review Mission | · | | | | |
| Last PDS Update | 16 Sep 2020 | | | | |

Grant 0738-UZB

| Financing Plan | | | Grant Utilization | | | |
|----------------|--------------------------------|----------------------------|-------------------|--------|----------------|--|
| | Total (Amount in US\$ million) | Date | ADB | Others | Net Percentage | |
| Project Cost | 3.00 | Cumulative Contract Awards | | | | |
| ADB | 3.00 | - | 0.00 | 0.00 | % | |
| Counterpart | 0.00 | Cumulative Disbursements | | | | |
| Cofinancing | 0.00 | - | 0.00 | 0.00 | % | |

| Project Page | https://www.adb.org/projects/54390-001/main |
|-------------------------|---|
| Request for Information | http://www.adb.org/forms/request-information-form?subject=54390-001 |
| Date Generated | 19 September 2020 |

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.